This $234,000 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports a two-year clinical research initiative (August 1, 2025 – July 31, 2027) led by the University of Michigan. The project will conduct a 100-patient clinical trial to evaluate the prevalence and treatment of rectal evacuation disorders in patients with hemorrhoidal bleeding—a...
This National Science Foundation (NSF) Project Grant, awarded under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070), provides $168,690 to the Florida Institute of Technology Inc. (Florida TECH) to develop a theragnostic (therapeutic + diagnostic) system for inflammatory bowel diseases (IBD). The project aims to model the complex interplay of host, microbial, and environmental factors that trigger IBD using data science, and then leverage synthetic biology and...
This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...
Federal Project Grant Award Summary The University of California, San Francisco received a $512,595 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 15, 2026, with completion targeted for February 28, 2030. This award funds basic biomedical research investigating a novel neural circuit mechanism that regulates urinary and fecal...
Federal Grant Award Summary Massachusetts General Hospital received a $393,870 K23 Patient-Oriented Research Career Development Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective June 3, 2025 through March 31, 2030. The award supports the development and evaluation of "WISH," a novel 9-week phone-based positive psychology intervention (PPI)...
Federal Project Grant Award Summary Lumina Medical LLC received $324,678 in federal funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and advance a motorized, girth-adjustable anal dilator device. The award, issued on June 2, 2025, with completion targeted for August 31, 2026, supports the design and validation of an innovative medical device that...
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
Federal Grant Award Summary Cedars-Sinai Medical Center received a $349,160 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 9, 2025, with a completion date of June 30, 2028. The grant supports a multicenter pilot and feasibility study developing artificial intelligence (AI)-enhanced virtual reality (VR) cognitive behavioral...
Sentire Medical Systems, Inc. was awarded a $256,000 National Science Foundation Project Grant to develop an intraoperative monitoring device to detect bowel injuries during laparoscopic surgical procedures. The goal of the NSF Technology, Innovation, and Partnerships program is to advance science and engineering research leading to breakthrough technologies that address national challenges. Through this award, Sentire Medical will characterize gases present during laparoscopic surgery to...
Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the University of Maryland Baltimore County a $296,746 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) on September 1, 2025, with a completion date of August 31, 2029. The project, titled "CyberGut: Cyber-Physical System for Closed-Loop Control of Gastric Motility," develops an intelligent adaptive...
FECOBIONICS MONITORING AND PREDICTION OF BIOFEEDBACK THERAPY OUTCOME IN PATIENTS WITH OBSTRUCTED DEFECATION. - ABSTRACT DEFECATORY DISORDERS AFFECT 25% OF THE POPULATION AND THEY ARE POORLY RECOGNIZED AND TREATED. THE INCIDENCE OF DEFECATORY DISORDERS INCLUDING CHRONIC CONSTIPATION IS RISING AND IT POSES A MAJOR HEALTHCARE BURDEN. THE UNDERLYING MECHANISMS FOR THESE DISORDERS ARE OFTEN NOT WELL UNDERSTOOD. OBSTRUCTED DEFECATION (DYSSYNERGIA) HAS SEVERAL CAUSES AND IS SUBDIVIDED IN FOUR SUBTYPES. DESPITE THE HIGH PREVALENCE AND INCIDENCE, DIAGNOSTICS AND TREATMENT OPTIONS ARE SPARSE. A SIGNIFICANT PROBLEM IN ANORECTAL PHYSIOLOGY TESTING IS A LACK OF PHYSIOLOGICALLY RELEVANT AND PRACTICAL DIAGNOSTIC TEST FOR IDENTIFYING THE UNDERLYING MECHANISMS TO IDENTIFY PROPER TREATMENT. CURRENT DIAGNOSTIC TESTS PROVIDE INCOMPLETE AND OFTEN CONFLICTING INFORMATION BECAUSE THEY DO NOT SIMULATE FECES OR THE DEFECATION PROCESS. NOT SURPRISINGLY, RESULTS OF THESE TESTS CORRELATE POORLY WITH SYMPTOMS AND TREATMENT OUTCOMES. BIOFEEDBACK THERAPY IS A WELL-ESTABLISHED THERAPY FOR OBSTRUCTED DEFECATION BUT DESPITE THE SUBSTANTIAL POTENTIAL AND PROMISING RESULTS, BIOFEEDBACK THERAPY IS ONLY DONE AT SPECIALIZED CENTERS AND SHOULD BE ADVANCED CLOSER TO THE POINT OF CARE. THE OBJECTIVE OF THIS SMALL R01 PROPOSAL IS TO MONITOR AND PREDICT THE OUTCOME OF BIOFEEDBACK THERAPY BASED ON UNPRECEDENTED INTEGRATED VISUAL FEEDBACK FROM THE NOVEL SIMULATED FECES DEVICE TERMED FECOBIONICS. THE DEVICE IS ELECTRONIC SIMULATED FECES THAT HAS THE CONSISTENCY AND SHAPE OF NORMAL STOOL. FECOBIONICS WILL PROVIDE MECHANISTIC UNDERSTANDING OF DEFECATION FOR THE EXAMINER BY VISUALIZING THE GEOMETRIC (CROSS-SECTIONAL AREA, BENDING AND SHAPE OF DEVICE) AND MANOMETRIC PROFILES OF THE SIMULATED FECES BEFORE AND DURING DEFECATION. THE CENTRAL HYPOTHESIS IS THAT THE FECOBIONICS DEVICE THAT MIMICS NATURAL DYNAMIC DEFECATION PROVIDES VALID DATA ON RECTAL EMPTYING ATTEMPTS FOR THE VARIOUS COMPONENTS OF THE DEFECATORY SYSTEM SUCH AS THE TONE OF ANAL SPHINCTERS AND PUBORECTALIS MUSCLE, AND ON MECHANOSENSORY PROPERTIES. THE OBJECTIVE IS TO MONITOR AND PREDICT BIOFEEDBACK THERAPY BASED ON MECHANISM-BASED AND HIGHLY INTEGRATED DATA THAT CAN BE VISUALIZED DURING ANORECTAL NEUROMUSCULAR EXERCISES. FOR THE PROPOSED STUDIES, WE WILL SELECT DYSSYNERGIA PATIENTS, WHO WILL BE MONITORED WITH FECOBIONICS BEFORE, DURING AND AFTER BIOFEEDBACK THERAPY. THE HYPOTHESIS IS FECOBIONICS DATA WILL CORRELATE BETTER TO SYMPTOMS BASED ON CONSTIPATION SCORES THAN CONVENTIONAL TECHNOLOGIES AND THAT SUCH DATA CAN BE USED TO PREDICT RESPONDERS AND NON-RESPONDERS TO THERAPY. OUR PROPOSAL SEEKS TO SHIFT CURRENT RESEARCH IN CONSTIPATION THERAPY BY USE OF A NOVEL DEVICE THAT PROVIDES MECHANISTIC INSIGHTS BY SIMULATING DEFECATION PATHOPHYSIOLOGICALLY AND EXAMINING THE MECHANISTIC CHANGES MULTI-DIMENSIONALLY: PRESSURE, DEFORMABILITY, BIOMECHANICS, AND TOPOGRAPHIC CHANGES TO MONITOR UNDERLYING DEFECTS IN PATIENTS WITH OBSTRUCTED DEFECATION, ESPECIALLY IN DYSSYNERGIA. THE UNIQUE ASPECTS OF OUR PROPOSAL ARE TO SIMULATE STOOL WITH A BIONICS DEVICE THAT INTEGRATES MULTIPLE VARIABLES THAT EXAMINE THE MECHANISTIC UNDERPINNINGS OF OBSTRUCTED DEFECATION. THE IMPACT OF THIS PROJECT IS TO SHED NEW UNDERSTANDING OF CONSTIPATION AND TO PREDICT RESPONDERS. THIS WILL FACILITATE DEVELOPMENT OF INNOVATIVE BOWEL MANAGEMENT PROGRAMS USING FECOBIONICS AS THE BIOFEEDBACK THERAPY TOOL.